IDH2 and acute myeloid leukemia: Enasidenib was granted regulatory approval by the FDA on 1 August 2017 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test [130].